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ABSTRACT
Background: Vitamin D has several roles, namely physiological function of calcium 
and bone metabolism, cell growth and differentiation, immune and cardiovascular 
function. Vitamin D deficiency can cause the risk of cancer. Head and neck cancer 
is one of the cancers that occur due to vitamin D deficiency in the body. This 
literature review was to asses and evaluate the impact and benefits of vitamin D 
supplementation for head and neck cancer. 
Discussion: A study found an association between vitamin D supplementation and 
a low risk of recurrence in conditions of high total vitamin D levels. Another study 
found a significant increase in quality of life (QOL). The primary mechanism of 
vitamin D action is mediated through binding of either 1,25(OH)2D3 (active form) or 
25(OH)D (less active form) to the VDR, which is a member of the nuclear receptor 
superfamily of steroid and thyroid hormones with gene-regulatory and consequent 
anti-proliferative properties.
Conclusions: Vitamin D supplementation provides a role in improving the condition 
of patients with head and neck cancer. Both in terms of suppressing recurrence 
and in terms of increasing quality of life.
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Vitamin D is a steroid hormone, consisting 
of cholecalciferol (vitamin D3) which is an en-
dogenous form and synthesized in the skin by 
the action of ultraviolet light, and ergocalciferol 
(vitamin D2) which is an exogenous form and 
is obtained through consumption of food or 
supplements1–4. In the liver and other tissues 
ergocalciferol and cholecalciferol are convert-
ed to 25(OH)D. Then 25(OH)D is metabolized 
to its active form 1,25 dihydroxyvitamin D 
[1,25(OH)2D] by 25-hydroxyvitamin D-1-α-hy-
droxylase, or CYP27B1. This hydroxylation 
occurs mainly in the kidneys, but extra kidney 
tissue and immune cells are also capable of 
producing 1,25(OH)2D. The active form of Vita-
min D (1,25-dihydroxyvitamin D) is a powerful 
immunomodulator with receptors in macro-
phages, monocytes T and B lymphocytes 5–8. 
 To determine vitamin D status Serum 
25(OH)D was used, although the cut off val-
ue for classifying insufficiency/deficiency was 
inconsistent. However, a general definition 
for vitamin D status based on serum levels of 
25(OH)D has been widely established and ad-
opted: Deficiency < 20 ng/ml (50 nmol/l); in-
sufficient 21-29 ng/ml (52-72 nmol/l); enough > 
30 ng / ml (> 75 nmol / l) 4,9.  According to The 
National Academy of Sciences recommends 
the following daily intakes of vitamin D : 1 to 50 
years, 5 µg (200 IU); 51-70 years, 10 µg (400 
IU) is older than 71 years 15 µg (600 IU). In 
one study, 12,5 µg (500 IU) per day was asso-
ciated with 30 ng / mL 25 (OH) D levels 10.
Vitamin D has many functions in terms of 
suppressing cancer through its various effects 
as antitumor, antiproliferative, apoptosis and 
angiogenesis. Therefore, individuals with low 
serum vitamin D levels will have a high risk of 
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developing cancer. Head and neck cancers 
including oral cancer have a low response to 
chemotherapy and anti-cancer drugs. There-
fore, it is very possible for resistance to che-
motherapy and radiotherapy. Vitamin D is ex-
pected to provide a better response to cancer 
therapy and prevent recurrence2,11–18.
Some studies show that vitamin D can play 
an important role in the incidence of cancer. 
It is estimated that vitamin D acts through vi-
tamin D receptors (VDR) to produce anti-can-
cer effects and has the potential to regulate 
immune cells. This known transcription phe-
nomenon is responsive to binding to vitamin 
D, expressed in many normal and malignant 
tissues, binds to target genes that regulate cell 
growth, and has been shown to be removed or 
lowered regulated in tumor tissue. Preclinical 
studies of the biologically active forms of vita-
min D, 1,25(OH)2D also support vitamin D-me-
diated antiproliferation and induce apoptosis of 
cancer cells19,20.
To assess and determine the efficacy of vi-
tamin D supplementation in the treatment of 
head and neck cancer in terms of reducing the 
risk of recurrence and improving quality of life.
LITERATURE REVIEW
Literature search was performed in PubMed 
and Google Scholar databases between Janu-
ary 2008 until September 2018. The following 
keywords were used in the search “vitamin D 
and oral cancer” or “vitamin D head and neck 
cancer”. Titles and abstract of each publica-
tion were repeatedly reviewed in the search 
process. The entire article was checked when 
necessary. To avoid any possible reports 
missed in the literature search, we reviewed 
references from relevant articles and related 
reviews to identify potensial relevant studies.    
The inclusion criteria will be used for select-
ing articles as follows :
• English and Indonesian language arti-
cles published between January 2008 
until September 2018
• Study type cohort study and randomized 
controlled trials (RCTs) with any dose 
or formulation of vitamin D intervention 
compared with placebo or no treatment
Figure 1  Flowchart of Study Selection
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• Head and neck cancer based on requr-
rance and quality of life
Data extraction sumarized in 4 tables. There 
were two outcome measures we used in order 
to know the role of supplementation vitamin D 
in included studies. The first outcome was the 
requrrance of cancer and the second outcome 
was of quality of life.
Number of 51.543 articles we got from 
PubMed and Google scholar, we filter articles 
based on title, abstract and keywords to find 10 
articles, then we read 10 articles in full text, 5 
articles do not enter criteria, namely 4 articles 
not included in the title and 1 case study arti-
Tabel 1. Study Characteristic
Tabel 2. Sample Characteristic
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cle. Therefore, the author gets 5 articles that 
match the inclusion criteria. 
The 5 articles that the research design ob-
tained, the following were two RCT (Random-
ized Control Study) designs and three Cohort 
research designs (longitudinal observational 
studies, prospective observational studies, 
and prospective cohort studies). The type of 
head and neck cancer that occurs is papillary 
thyroid carcinoma, head and neck squamous 
carcinoma, esophageal cancer, oral squamous 
cell carcinoma and head and neck cancer (Ta-
ble 1). The articles was published in 2009 un-
til 2018. Total sample 572 peoples, with male 
gender as many as 492 people and women as 
many as 56 people for 4 articles because 1 ar-
ticle does not explain about gender. The sam-
ple age range is 22-92 years (Table 2).
Supplementation of vitamin D varies as 
low as 1 µg per day and the largest is 25 µg 
per day. The outcome of reducing recurrence 
can be seen in 3 authors, Yokosawa, Eva B. 
et.al.19, Lyel oh, Jong.et.al.21, Walsh, Jarrett 
E.et.al.22 and the outcome of improving qual-
ity of life can be seen from 3 authors namely 
Anand, Akshay, et al.11, Lyel Roh, Jong.et.al.21 
and Wang, Lu.et.al.23 (Table 3 and Table 4).
Yokosawa, Eva B, et al. found that recur-
rence occurred in 9.2% of patients who re-
ceived vitamin D supplementation of more than 
16.875 µg per day and 12.96% of recurrences 
occurred at vitamin D supplementation of less 
than 5 µg per day19 (Tabel 3). 
Tabel 4. Supplementation Dose and Quality of Life Outcome
Tabel 3. Supplementation Dose and Recurrance Risk Outcome 
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DISCUSSION
Geographical variation is very important in 
terms of mortality in cancer, which is associ-
ated with latitude and ultraviolet-B radiation in 
the sun. Photosynthesis of vitamin D3 (chole-
calsiferol) occurs in the skin by the action of ul-
traviolet-B radiation in the sun. Overall vitamin 
D status in a person depends on cholecalcif-
erol and ergocalciferol (Vitamin D2). 25-Dyhy-
droxyvitamin D, is a major form of circulation 
of vitamin D, reflecting the cumulative effect of 
sun exposure and dietary intake of vitamin D 
1–4,24,25. 
The primary mechanism of vitamin D ac-
tion is mediated through binding of either 
1,25(OH)2 D3 (active form) or 25(OH)D (less 
active form) to the VDR, which is a member 
of the nuclear receptor superfamily of steroid 
and thyroid hormones with gene-regulatory 
and consequent anti-proliferative properties2. 
Binding of 1,25(OH)2D to the VDR (either 
in the cell nucleus or in the cytoplasm) pro-
motes association of the VDR–1,25(OH)2D 
complex with the retinoid X receptor (RXR)2. 
The 1,25(OH)2D–VDR–RXR complex binds to 
vitamin D-response elements in DNA which 
operate to initiate gene transcription. Activa-
tion of the VDR by 1,25(OH)2D can restore or 
enhance proapoptotic effects in different can-
cer cells through transcriptional activation of 
bax and p-calpain, two effective proapoptotic 
proteins. VDR–vitamin D activation also been 
demonstrated to increase mRNA expression of 
transforming growth factor, a potent antiprolif-
erative cytokine in normal and early stage can-
cer cells; superoxide dismutase, which may 
reduce oxidative stress-induced DNA damage 
and loss to DNA repair mechanisms that con-
tribute to carcinogenesis and inflammatory cy-
tokine production; as well as cyclin-dependent 
kinase (CDK) inhibitor p21, RBL2, RBLP6 and 
forkhead box O (FOXO) tumour suppressors 
that function to counteract MAPK-mediated 
phosphorylation and growth2. VDR activation 
may also facilitate transcriptional repression of 
Bc1-2 and telomerase (pro-survival proteins), 
as well as CDK1 mRNA, which encodes a re-
quired protein for cellcycle progression. Sup-
pression of vascular endothelial growth factor, 
responsible for angiogenesis, as well as the 
pro-inflammatory cyclooxygenase-2, was also 
observed. In addition, 1,25(OH)2D may disrupt 
the function of β-catenin, the terminal mediator 
of Wnt signalling, which activates transcription 
of genes whose protein products (c-Myc and 
cyclin D1) control cell proliferation, as well as 
insulin-like growth factor–stimulated tumour 
growth2.
A study found an association between vi-
tamin D supplementation and a low risk of 
recurrence in conditions of high total vitamin 
D levels19. Another study found a significant 
increase in quality of life (QOL) and Dis-
ease-Free Survival (DFS) in esophageal can-
cer (EC) patients who underwent esophagec-
tomy who received vitamin D supplementation 
during cancer treatment and post recovery23. 
T-cell functional competence is very important 
to stimulate antitumor immune reactivity. How-
ever, patients with head and neck squamous 
cell carcinoma have low immunity. There are 
several immune inhibitory mechanisms medi-
ated by HNSCC (Head and Neck Squamous 
Cell Carcinoma), including the induction of 
their immune suppressing cells that block the 
host’s immune reactivity. This study shows 
that treatment of patients with advanced HN-
SCC disease with vitamin D supplementation 
reduces the level of immune inhibitory CD34 
cells in peripheral blood and simultaneously in-
creases peripheral blood cell immune reactivi-
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ty22.  Likewise, prior study said that low vitamin 
D levels are closely related to the risk of neck 
and head cancer, then he said that vitamin D 
supplementation significantly improved healing 
of erythema, lichenoid, edema, ulceration and 
pain in patient oral cancer 11.
There are many benefits of vitamin D for 
body health. Therefore, we must always keep 
vitamin D levels in the body in sufficient condi-
tion. In addition to providing preventive benefits 
in the prevention of infections, cardiovascular 
disorders, and cancer26. Vitamin D supplemen-
tation provides curative benefits in cancer pa-
tients in terms of suppressing the cancer itself, 
preventing recurrence and improving quality of 
life11,19,21–23.
CONCLUSION
Vitamin D supplementation provides a role 
in improving the condition of patients with head 
and neck cancer. Both in terms of suppressing 
recurrence and in terms of increasing quality of 
life. But unfortunately there is still few research 
on vitamin D supplementation on oral cancer 
or head and neck cancer, therefore more re-
searchers are expected to conduct research re-
lated to the role of vitamin D, especially in terms 
of oral cavity health.
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